CSF3 and AL amyloidosis: Our study supports the use of AMD3100 for slowing or preventing the onset of PTOA following injury.The treatment of AMD3100 combined with granulocyte-colony stimulated factor had been approved by FDA for patients with multiple myeloma and non-Hodgkin’s lymphoma, which proved that AMD3100 is safe and valid.